Evaluating the Impact of a Youth-Led Sexual Violence Prevention Program: Youth Leadership Retreat Outcomes

Prevention Science - Involving youth in developing and implementing prevention programs to reduce sexual violence (SV) has the potential to improve prevention outcomes. However, there has been...     

Mood,Dietary Restraint,and Women's Smoking and Eating Urges

Women may have difficulty maintaining smoking cessation efforts due to negative affect and fear of weight gain. Dieting smokers who rely on cigarettes for affect regulation and weight management may be especially prone to weight gain and smoking relapse following initial smoking abstinence. The present study, which included 82 women smokers, assessed the relationship between dieting status, self-efficacy, and temptation to smoke and eat following a depressing or elating mood induction. Women with high levels of dietary restraint (i.e., more dieting behavior) had more confidence in their ability to refrain from smoking when in the elated mood condition, and they were more tempted to smoke when in the depressed condition. At low levels of dietary restraint (i.e., less dieting behavior), depressed or elated mood condition appeared to have little impact on women's confidence to refrain from smoking or their temptation to smoke. Dieting status seems to moderate the impact of positive and negative mood states, especially with respect to women's smoking behavior. These findings may have implications for dieters who are trying to quit smoking and also maintain their weight.     

Extensions to the two‐stage randomized trial design for testing treatment,self‐selection,and treatment preference effects to binary outcomes

While traditional clinical trials seek to determine treatment efficacy within a specified population, they often ignore the role of a patient's treatment preference on his or her treatment response. The two‐stage (doubly) randomized preference trial design provides one approach for researchers seeking to disentangle preference effects from treatment effects. Currently, this two‐stage design is limited to the design and analysis of continuous outcome variables; in this presentation, we extend this current design to include binary variables. We present test statistics for testing preference, selection, and treatment effects in a two‐stage randomized design with a binary outcome measure, with and without stratification. We also derive closed‐form sample size formulas to indicate the number of patients needed to detect each effect. A series of simulation studies explore the properties and efficiency of both the unstratified and stratified two‐stage randomized trial designs. Finally, we demonstrate the applicability of these methods using an example of a trial of Hepatitis C treatment.     

Specialized Inpatient Psychiatry for Serious Behavioral Disturbance in Autism and Intellectual Disability

Psychiatric hospitalization of children with autism spectrum disorder and/or intellectual disability is common, however, the effectiveness of this intervention is largely unknown. Thirty-eight clinically-referred children 8–19 years old admitted to a specialized inpatient psychiatry unit were assessed by a consistent caregiver on the Aberrant Behavior Checklist-Irritability (ABC-I) subscale at admission, discharge and 2 months post discharge. There was a decrease in the mean ABC-I score from admission (27.3, SD 7.4) to discharge (11.9, SD 8.8), which was sustained at 2 months post discharge (14.8, SD 9.3) (p < 0.001). Seventy-eight percent of the subjects were rated as “Improved” on the clinician Clinical Global Impressions Improvement scale at discharge. The study is limited by lack of a control group, but offers preliminary evidence for specialized inpatient psychiatry as an intervention for serious behavioral disturbance in this population.     

Role of visfatin, insulin-like growth factor-I and insulin in fetal growth

OBJECTIVE: IGF-I and insulin are the main regulators of intrauterine and postnatal growth. Adipose tissue secreted cytokines are implicated in intrauterine growth. The relevant function of the adipocytokine visfatin is unknown. MATERIALS AND METHODS: Serum visfatin, IGF-I and insulin levels were measured by enzyme immunoassays in 40 singleton full-term fetuses and neonates on postnatal days 1(N1) and 4 (N4). RESULTS: No significant correlations exist between visfatin and IGF-I or insulin. N1 and N4 visfatin positively correlated with customized (adjusted) birth weight centiles (r=0.511, P=0.021, and r=0.597, P=0.005, respectively). Fetal and N1 IGF-I positively correlated with customized centiles (r=0.608, P<0.001 and r=0.485, P=0.006, respectively). Fetal insulin positively correlated with customized centiles (r=0.654, P=0.021). CONCLUSIONS: Potential implication of visfatin in fetal growth is probably not mediated by IGF-I or insulin. Although a more active role cannot be excluded, visfatin may simply represent a marker of fat accumulation.